Q2 FY2026 EarningsQ2 FY26 missed consensus expectations on the bottom line, with a GAAP net loss of $44.1M compared to the anticipated $35.8M. Diluted EPS of -$0.14 was lower than the mean estimate of -$0.11, driven by elevated R&D spending to accelerate the ERAS-0015 program. However, the balance sheet was significantly bolstered by a $632.5M upsized offering in July, providing a robust cash runway for three upcoming registration-enabling trials in pancreatic and lung cancers.
Financial report interval: 2026.03.30 - 2026.06.30
Overview: Erasca(ERAS) the EBIT is -47.62 M (-24.9%), Miss estimate;the EPS is -0.14 (-16.67%), Miss estimate.
Actual
YoY
Estimate
YoY
Vs estimate
YoY
Revenue
TBA--
0.00B--
----
EBITMiss expectations
-0.05B24.90%
-0.04B4.53%
-0.01B20.37%
EPSMiss expectations
-0.1416.67%
-0.11424.83%
-0.025821.50%
Revenue
ActualEstimateUnit: USD
qf
EBIT
ActualEstimateUnit: USD
qf
Net income
ActualEstimateUnit: USD
qf
EPS
ActualEstimateUnit: USD
qf